Clinica Baviera (CBAV) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
31 Jul, 2026Executive summary
Revenue grew 10% year-over-year to €169.9 million in H1 2026, with all countries contributing to growth.
Net income increased 17% to €26.7 million compared to H1 2025.
EBITDA rose 14% to €50.6 million, with margin improvements in Spain and Italy.
Expansion continued with new clinics in Spain, Germany, and Italy, supporting sales growth.
Financial highlights
Operating expenses increased 8% year-over-year, reaching €119.4 million.
EBIT grew 12% to €37.1 million, while profit before taxes rose 14% to €37.1 million.
Cash flow from operations was stable at €42.9 million.
CAPEX totaled €12.4 million, mainly for new openings and renovations.
Outlook and guidance
New clinics in Spain, Germany, and Italy are expected to drive further growth.
The Rome clinic in Italy is set to begin operations in September, supporting continued expansion.
Latest events from Clinica Baviera
- Q1 2026 saw 8% revenue growth and 14% higher net income, driven by clinic expansion.CBAV
Q1 2026 - Revenue and profit rose double digits, with strong expansion and robust financial position.CBAV
Q4 2025 - Revenue up 16% and EBITDA up 12% year-over-year, with strong expansion and share price growth.CBAV
Q3 2025 - Revenue up 18% to €154.7M; EBITDA and core market growth offset UK and Italy headwinds.CBAV
Q2 2025 - Revenue up 16% and UK expansion via Optimax acquisition mark a growth-focused quarter.CBAV
Q3 2024 - Double-digit growth and a strategic UK acquisition drove strong 1H 2024 results.CBAV
Q2 2024 - Revenue up 21% and net income up 4% in Q1 2025, with strong cash position.CBAV
Q1 2025 - Record revenue and profit growth, UK expansion, and higher dividends highlight 2024.CBAV
Q4 2024